 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that IBRX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

ImmunityBio (IBRX, $5.33) Stochastic Oscillator left the oversold zone on April 01, 2024

Over the last three days, A.I.dvisor has detected that IBRX's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

ImmunityBio (IBRX, $5.33) Aroon Indicator entered an Uptrend on April 01, 2024.

ImmunityBio (IBRX, $5.35) Aroon Indicator entered an Uptrend on March 28, 2024.

ImmunityBio (NASDAQ:IBRX  Free Report) had its price objective hoisted by Piper Sandler from $4.00 to $5.00 in a research report released on Monday, Benzinga reports. Piper Sandler currently...

Piper Sandler Raises ImmunityBio (NASDAQ:IBRX) Price Target to $5.00

ImmunityBio (IBRX, $5.45) Aroon Indicator entered an Uptrend on March 27, 2024.

ImmunityBio (IBRX, $5.13) Aroon Indicator entered an Uptrend on March 26, 2024.

This is a Bearish indicator signaling IBRX's price could decline from here. Traders may explore shorting the stock or put options...

ImmunityBio (IBRX, $5.13) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 26, 2024

ImmunityBio (NASDAQ:IBRX  Free Report) had its price objective boosted by Piper Sandler from $4.00 to $5.00 in a report released on Monday, Benzinga reports. The firm currently has a neutral...

ImmunityBio (NASDAQ:IBRX) Price Target Raised to $5.00 at Piper Sandler

ImmunityBio (IBRX, $5.44) Aroon Indicator entered an Uptrend on March 25, 2024.

This is a signal that IBRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

ImmunityBio (IBRX, $6.07) RSI Indicator left the overbought zone on March 22, 2024

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Volume (M)	3.52M
52-Wk High	$6.93
52-Wk Low	$1.25

IBRX ImmunityBio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals